Key Points
- CEO John Aballi sold 15,698 shares on March 3 at an average price of $3.62 for $56,826.76, reducing his stake by 2.23% to 687,299 shares (worth ~$2.49M); he also sold 11,430 shares on Feb 24.
- XGN stock was down 13.1%, trading at $3.12 with 416,329 shares exchanged (vs. avg. vol. 522,380), a market cap of ~$70.7M and a negative P/E of -3.39; the 50- and 200-day moving averages are $4.46 and $7.73, respectively.
- Analysts have trimmed price targets but maintain a consensus "Moderate Buy" with a $11.43 target, while institutional investors control roughly 75.25% of the company’s shares.
Exagen Inc. (NASDAQ:XGN - Get Free Report) CEO John Aballi sold 15,698 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $3.62, for a total value of $56,826.76. Following the transaction, the chief executive officer owned 687,299 shares in the company, valued at $2,488,022.38. This trade represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
John Aballi also recently made the following trade(s):
- On Tuesday, February 24th, John Aballi sold 11,430 shares of Exagen stock. The shares were sold at an average price of $3.61, for a total transaction of $41,262.30.
Exagen Trading Down 13.1%
XGN stock traded down $0.47 on Thursday, hitting $3.12. 416,329 shares of the company were exchanged, compared to its average volume of 522,380. The stock has a market capitalization of $70.70 million, a price-to-earnings ratio of -3.39 and a beta of 1.88. The business's fifty day moving average is $4.46 and its two-hundred day moving average is $7.73. Exagen Inc. has a twelve month low of $2.77 and a twelve month high of $12.23. The company has a debt-to-equity ratio of 1.35, a current ratio of 4.08 and a quick ratio of 4.08.
Analyst Ratings Changes
A number of analysts have recently issued reports on the company. B. Riley Financial reiterated a "buy" rating and set a $8.00 target price (down from $18.00) on shares of Exagen in a report on Friday, January 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of Exagen in a research report on Wednesday, January 21st. BTIG Research dropped their target price on Exagen from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, February 17th. Finally, TD Cowen decreased their price target on Exagen from $13.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, February 24th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Exagen has a consensus rating of "Moderate Buy" and a consensus price target of $11.43.
Get Our Latest Report on Exagen
Institutional Investors Weigh In On Exagen
A number of hedge funds have recently bought and sold shares of the business. Balyasny Asset Management L.P. acquired a new stake in Exagen in the second quarter valued at $5,017,000. Invesco Ltd. acquired a new stake in shares of Exagen in the 3rd quarter valued at about $7,420,000. Mink Brook Asset Management LLC lifted its position in shares of Exagen by 784.3% during the fourth quarter. Mink Brook Asset Management LLC now owns 353,727 shares of the company's stock worth $2,151,000 after purchasing an additional 313,727 shares during the last quarter. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Exagen during the fourth quarter worth about $1,520,000. Finally, Millennium Management LLC acquired a new position in Exagen in the third quarter worth about $2,716,000. Institutional investors and hedge funds own 75.25% of the company's stock.
Exagen Company Profile
(
Get Free Report)
Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.
The company's flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren's panel.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
